VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Novel microneedle patch accelerates healing of chronic diabetic wounds using light

Researchers from Nanjing Drum Tower Hospital, Southeast University, and Wenzhou Medical University have developed a novel microneedle patch that combines MXene hydrogel with nitric oxide (NO) and hypoxia-inducible factor-1α (HIF-1α) plasmid for enhanced diabetic wound treatment.

10 Mar 2026

Armored CAR T cells overcome tumor defenses in solid cancers

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block their attack and fuel tumor growth.

4 Mar 2026

Distinct gut toxicity patterns emerge with targeted cancer treatments

A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection."

20 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Can hot baths lower high blood pressure?

A review highlights hot water immersion's potential in lowering blood pressure, emphasizing it as an adjunct therapy alongside traditional treatments.

12 Feb 2026

Transcription factor HOXD13 drives melanoma growth and immune evasion

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade attack by the body's immune system, a new study shows.

11 Feb 2026

Tear biosensor detects diabetic retinopathy biomarkers for early diagnosis

Tear fluid is emerging as an attractive source of diagnostic information because it can be collected easily and non-invasively.

9 Feb 2026

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor Microenvironment Promotes Sorafenib Resistance in Hepatocellular Carcinoma via the 14-3-3η-Modified Tumor-Associated Proteome" in the Chinese Medical Journal.

23 Jan 2026

Pitavastatin shows pomise in overcoming chemotherapy resistance in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.

7 Jan 2026

Remodeling the tumor microenvironment to unlock CAR-T cell potential

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME).

22 Dec 2025

Scientists map how cinnamon’s bioactives interact with cancer signaling

This review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative stress, apoptosis, and angiogenesis through multiple cancer-related signaling pathways. While biologically plausible, the findings are largely limited to cell and animal models, underscoring the need for pharmacokinetic, safety, and clinical validation.

15 Dec 2025

Eli Lilly’s Adverum move: The future of ocular gene therapy at the 4th Ophthalmic Drug Delivery Summit

The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery.

From Hanson Wade Group - 4th Ophthalmic Drug Delivery Summit 26 Nov 2025

Advances in diagnosis and management of chronic subdural hematoma

Chronic subdural hematoma (CSDH) is one of the most common neurosurgical conditions, particularly among the elderly, with an annual incidence ranging from 1.7 to 20.6 per 100,000 people.

18 Nov 2025

Toward precision diagnosis and treatment of radiation-induced brain injury

Radiation-induced brain injury (RIBI) is a serious and often delayed complication of cranial radiotherapy, which remains a cornerstone in the treatment of brain tumors such as gliomas, metastases, and lymphomas.

18 Nov 2025

Understanding leptin's dual function in MAFLD pathogenesis

Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, intricately linked with obesity, type 2 diabetes (T2DM), and metabolic syndrome.

14 Nov 2025

Flexible drug-delivery patch can promote tissue healing after a heart attack

MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help promote healing and regeneration of cardiac tissue.

4 Nov 2025

Therapeutic potential of Scleromitrion diffusum in gastric cancer treatment

Gastric cancer remains a major global health challenge, characterized by high mortality and limited therapeutic efficacy, especially in advanced stages.

30 Oct 2025

Wireless retinal implant restores sight in patients blinded by advanced macular degeneration

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic atrophy caused by age-related macular degeneration. After one year, 81% achieved clinically meaningful vision gains and most could read at home using prosthetic vision.

28 Oct 2025

Novel computational platform can design synthetic protein receptors from scratch

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), have revolutionized cancer treatment.

28 Oct 2025

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

18 Oct 2025